Marquette Asset Management LLC raised its stake in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Free Report) by 89.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 47,166 shares of the company’s stock after purchasing an additional 22,301 shares during the period. Marquette […]
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Free Report) – Research analysts at Leerink Partnrs issued their Q1 2024 earnings estimates for Atea Pharmaceuticals in a research report issued to clients and investors on Monday, February 5th. Leerink Partnrs analyst R. Ruiz anticipates that the company will earn ($0.66) per share for the quarter. The consensus estimate […]
Sectoral Asset Management Inc. purchased a new stake in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Rating) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 281,403 shares of the company’s stock, valued at approximately $1,354,000. Sectoral Asset Management […]
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Rating) – Equities researchers at SVB Leerink raised their Q1 2023 earnings per share estimates for Atea Pharmaceuticals in a report issued on Wednesday, March 1st. SVB Leerink analyst R. Ruiz now anticipates that the company will post earnings of ($0.50) per share for the quarter, up from their […]
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Rating) saw a significant decrease in short interest during the month of September. As of September 15th, there was short interest totalling 2,300,000 shares, a decrease of 12.9% from the August 31st total of 2,640,000 shares. Based on an average trading volume of 471,500 shares, the short-interest ratio is […]